By Chris Wack Merck & Co. said it has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers. Merck s molnupiravir is an investigational oral antiviral agent being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed Covid-19. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck has entered into these agreements to speed up availability of molnupiravir in India and in other low- and middle-income countries following approvals or emergency authorization by local regulatory agencies. The agreements have been signed with Cipla Ltd., Dr. Reddy s Laboratories Ltd., Emcure Pharmaceuticals Ltd., Hetero Labs Ltd. and Sun Pharmaceutical Industries Ltd., five generics manufacturers with World Health Organization pre-qualified manufacturing facilities and experience as major drug suppliers.
Merck & Company, Inc (NYSE:MRK), Dr Reddy s Laboratories Ltd (NYSE:RDY) - Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Fetal alcohol syndrome Market Report Analysis And Insights For Highly Profitable Investment Decisi
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.